Aceminib shows sustained response rate in patients with chronic myelogenous leukemia at 48 weeks of follow-up

Aceminid is the first FDA-approved CML treatment that works by binding to the myristoyl pocket of ABL. This new mechanism of action, also known in the scientific literature as STAMP inhibitors, could help resolve resistance to TKI therapies in patients with chronic myelogenous leukemia and overcome mutations in the defective gene BCR-ABL1, which is involved in the overproduction of leukemia cells. Aximini continues to be studied in multiple treatment options for chronic myelogenous leukemia and chronic pancreatitis.

Responses were also durable in this latest analysis, with 60 of 62 patients treated with aceminib maintaining MMR1 at the last evaluation. Acemini continues to provide more favorable deep molecular responses (MRs) to MR. The incidence rates at 48 weeks were 10.8% and 7.6%, compared with 3.9% and 1.3% of patients treated with Bosoliv. Additionally, the cumulative proportion of patients achieving BCR-ABL1 levels was ≤1% higher than48 weeks in the aceminib group pan>Bosulif group (50.8% vs. 33.7%), which is a predictor of better long-term outcome in this heavily pretreated patient population.

The most common reasons for treatment discontinuation were 37 cases (23.6%) of patients receiving asiminib and < span>27patients (35.5%) who received Bosulif had poor efficacy. The median exposure to Scemblix was 15.4 months (range 0.0-37.3 months),Bosulif was 6.8 months (range 0.2-34.3 months). Safety and tolerability with prolonged exposure were consistent with the primary analysis of the ASCEMBL trial. The most common reported in this analysis (incidence ≥ 20%) Adverse reactions in the Scemblix group were thrombocytopenia (29.5%) and neutropenia (23.1%); and diarrhea (71.1%), nausea (46.1%), ALTelevated (28.9%), vomiting (26.3%), rash (23.7%), AST elevation (21.1%) and neutropenia (21.1%)